Missouri Trust & Investment Co purchased a new stake in Bath & Body Works, Inc. (NYSE:BBWI - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 36,910 shares of the company's stock, valued at approximately $1,178,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. First Community Trust NA bought a new position in shares of Bath & Body Works during the second quarter worth about $30,000. Livforsakringsbolaget Skandia Omsesidigt raised its position in shares of Bath & Body Works by 300.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,200 shares of the company's stock worth $38,000 after purchasing an additional 900 shares during the last quarter. EntryPoint Capital LLC raised its holdings in Bath & Body Works by 224.0% during the 1st quarter. EntryPoint Capital LLC now owns 1,471 shares of the company's stock valued at $74,000 after buying an additional 1,017 shares during the period. GAMMA Investing LLC grew its holdings in Bath & Body Works by 65.4% in the second quarter. GAMMA Investing LLC now owns 1,846 shares of the company's stock valued at $72,000 after purchasing an additional 730 shares during the period. Finally, Blue Trust Inc. boosted its position in shares of Bath & Body Works by 23.4% in the 2nd quarter. Blue Trust Inc. now owns 2,767 shares of the company's stock valued at $108,000 after purchasing an additional 524 shares during the period. 95.14% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Bath & Body Works
In other Bath & Body Works news, CEO Gina Boswell acquired 6,000 shares of the company's stock in a transaction dated Wednesday, October 9th. The shares were acquired at an average price of $29.64 per share, for a total transaction of $177,840.00. Following the acquisition, the chief executive officer now owns 242,987 shares in the company, valued at $7,202,134.68. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.27% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
BBWI has been the topic of several research reports. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Bath & Body Works from $57.00 to $54.00 and set a "buy" rating on the stock in a research report on Monday, August 26th. JPMorgan Chase & Co. decreased their target price on Bath & Body Works from $42.00 to $39.00 and set a "neutral" rating on the stock in a report on Thursday, August 29th. Robert W. Baird dropped their price target on Bath & Body Works from $54.00 to $45.00 and set an "outperform" rating on the stock in a research report on Thursday, August 29th. Citigroup reduced their target price on Bath & Body Works from $48.00 to $35.00 and set a "neutral" rating on the stock in a report on Tuesday, August 20th. Finally, UBS Group cut their price target on Bath & Body Works from $52.00 to $38.00 and set a "neutral" rating on the stock in a report on Thursday, August 29th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Bath & Body Works has an average rating of "Moderate Buy" and an average target price of $42.44.
Get Our Latest Stock Analysis on BBWI
Bath & Body Works Stock Performance
Shares of BBWI traded up $0.07 during mid-day trading on Tuesday, hitting $31.58. 3,413,885 shares of the company traded hands, compared to its average volume of 3,829,463. The stock has a market cap of $6.92 billion, a price-to-earnings ratio of 7.67, a P/E/G ratio of 0.95 and a beta of 1.79. The stock has a 50-day moving average price of $30.02 and a two-hundred day moving average price of $36.77. Bath & Body Works, Inc. has a 1 year low of $26.20 and a 1 year high of $52.99.
Bath & Body Works (NYSE:BBWI - Get Free Report) last announced its earnings results on Wednesday, August 28th. The company reported $0.37 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.02. The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.54 billion. Bath & Body Works had a negative return on equity of 41.94% and a net margin of 12.69%. On average, analysts forecast that Bath & Body Works, Inc. will post 3.18 EPS for the current year.
Bath & Body Works Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, December 6th. Stockholders of record on Friday, November 22nd will be paid a $0.20 dividend. The ex-dividend date is Friday, November 22nd. This represents a $0.80 annualized dividend and a dividend yield of 2.53%. Bath & Body Works's payout ratio is 19.37%.
Bath & Body Works Company Profile
(
Free Report)
Bath & Body Works, Inc operates a specialty retailer of home fragrance, body care, and soaps and sanitizer products. It sells its products under the Bath & Body Works, White Barn, and other brand names through retail stores and e-commerce sites located in the United States and Canada, as well as through international stores operated by partners under franchise, license, and wholesale arrangements.
Further Reading
Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.